Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Secukinumab in Active Psoriatic Arthritis
NCT04209205Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2020
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of secukinumab in psoriatic arthritis (PsA), sponsored by Novartis. Started Jan 2020; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04209205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209205.